Denali Therapeutics Inc.
Compounds, compositions and methods

Last updated:

Abstract:

The present disclosure relates generally to eukaryotic initiation factor 2B modulators, or a pharmaceutically acceptable salt, stereoisomer, mixture of stereoisomers, or prodrug thereof, and methods of making and using thereof.

Status:
Grant
Type:

Utility

Filling date:

28 May 2021

Issue date:

19 Apr 2022